Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: Expanding indications and novel combination strategies

Emily Hinchcliff; Shannon Neville Westin; Graziela Dal Molin; Christopher J. Lafargue; Robert L. Coleman

doi:10.1136/ijgc-2019-000499

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: Expanding indications and novel combination strategies

Emily Hinchcliff, Shannon Neville Westin, Graziela Dal Molin, Christopher J. Lafargue, Robert L. Coleman^*

^*Corresponding author for this work

Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key evidence for their use and therapeutic indications. Furthermore, we provide an overview of the development of PARPi resistance and the emerging role of PARPi combination therapies, including those with anti-angiogenic and immunotherapeutic agents.

Original language	English (US)
Pages (from-to)	956-968
Number of pages	13
Journal	International Journal of Gynecological Cancer
Volume	29
Issue number	5
DOIs	https://doi.org/10.1136/ijgc-2019-000499
State	Published - Jun 1 2019

Keywords

medical oncology
ovarian cancer

ASJC Scopus subject areas

Obstetrics and Gynecology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/ijgc-2019-000499

Cite this

@article{0cfa11410bfd49febc7ea341abbe2368,

title = "Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: Expanding indications and novel combination strategies",

abstract = "The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key evidence for their use and therapeutic indications. Furthermore, we provide an overview of the development of PARPi resistance and the emerging role of PARPi combination therapies, including those with anti-angiogenic and immunotherapeutic agents.",

keywords = "medical oncology, ovarian cancer",

author = "Emily Hinchcliff and Westin, {Shannon Neville} and {Dal Molin}, Graziela and Lafargue, {Christopher J.} and Coleman, {Robert L.}",

note = "Funding Information: This study was supported by the National Institutes of Health. This work is supported in part by the MD Anderson Cancer Center Support Grant (P30 CA016672), and a T32 training grant for gynecologic oncology (CA101642; to K.H. Lu) and the SPORE in Ovarian Cancer SPORE in ovarian cancer (P50 CA083639). Publisher Copyright: {\textcopyright} 2019 IGCS and ESGO.",

year = "2019",

month = jun,

day = "1",

doi = "10.1136/ijgc-2019-000499",

language = "English (US)",

volume = "29",

pages = "956--968",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Poly-ADP-ribose polymerase inhibitor use in ovarian cancer

T2 - Expanding indications and novel combination strategies

AU - Hinchcliff, Emily

AU - Westin, Shannon Neville

AU - Dal Molin, Graziela

AU - Lafargue, Christopher J.

AU - Coleman, Robert L.

N1 - Funding Information: This study was supported by the National Institutes of Health. This work is supported in part by the MD Anderson Cancer Center Support Grant (P30 CA016672), and a T32 training grant for gynecologic oncology (CA101642; to K.H. Lu) and the SPORE in Ovarian Cancer SPORE in ovarian cancer (P50 CA083639). Publisher Copyright: © 2019 IGCS and ESGO.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key evidence for their use and therapeutic indications. Furthermore, we provide an overview of the development of PARPi resistance and the emerging role of PARPi combination therapies, including those with anti-angiogenic and immunotherapeutic agents.

AB - The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food and Drug Administration approval since 2014. Given the rapidly expanding use of PARPi, this review aims to summarize the key evidence for their use and therapeutic indications. Furthermore, we provide an overview of the development of PARPi resistance and the emerging role of PARPi combination therapies, including those with anti-angiogenic and immunotherapeutic agents.

KW - medical oncology

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85067828307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067828307&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2019-000499

DO - 10.1136/ijgc-2019-000499

M3 - Article

C2 - 31118216

AN - SCOPUS:85067828307

SN - 1048-891X

VL - 29

SP - 956

EP - 968

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

IS - 5

ER -

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: Expanding indications and novel combination strategies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this